Has tucatinib/tucatinib been included in medical insurance reimbursement?

Tucatinib/Tucatinib, also known as Tukysa, is a cancer drug that has been approved for marketing overseas, such as the United States, the European Union, Canada and other places. However, as of now, this original drug has not been approved by my country's National Medical Products Administration and has not been officially launched in the domestic market, so it cannot be included in the scope of medical insurance. However, generic drugs of tucatinib have appeared overseas, produced by well-known manufacturers such as Laos No. 2 Factory, Bangladesh Ziska Pharmaceuticals, and Bangladesh Everest Pharmaceuticals. These generic drugs are highly consistent with the original drugs in terms of drug ingredients, but there may be differences in price and other aspects.

Tucatinib is mainly used to treat locally advanced breast cancer or has metastasized to other parts of the bodyHER2-positive breast cancer, a condition in which the HER2 protein is produced on the surface of cancer cells and stimulates cancer growth. It is often used in combination with capecitabine and trastuzumab, especially after at least two other treatments for HER2-positive cancer have failed. In addition, tucatinib is also approved for the treatment of unresectable or metastatic colorectal cancer, and its efficacy can be enhanced when combined with trastuzumab.

Tucatinib is a prescription drug and its treatment should be carried out under the guidance of a doctor with experience in cancer treatment. The recommended dose is 300 mg twice daily by mouth. Patients may also receive capecitabine and trastuzumab on specific days of the 21-day treatment cycle. Treatment can continue as long as the cancer is not getting worse and the patient can tolerate the side effects of the drugs. If certain serious side effects occur, your doctor may recommend reducing the dose of tucatinib or stopping treatment temporarily or even permanently.